Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2/3 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Neoplasms 2Sepsis 1Neutropenia 1Hematological Infection 1Gram-Negative Bacterial Infections 1Colorectal Neoplasms 1Anastomotic Leak 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 99Fluorouracil 90Capecitabine 86Radiotherapy 81Dexamethasone 81Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Drug Therapy 65Leucovorin 64Cetuximab 60Erlotinib Hydrochloride 56atezolizumab 53Sorafenib 53Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × Colistin × Clear all
NCT03397914 2020-09-16

Effect of Different Colistin Doses on Clinical Outcome of Pediatric Cancer Patients With Gram Negative Infections

National Cancer Institute, Egypt

Phase 4 Completed
70 enrolled

Neoplasms, Gram-Negative Bacterial Infections

NCT01931592 2017-05-08

CLEAR

University of Cologne

Phase 2/3 Terminated
29 enrolled

Neoplasms, Neutropenia, Sepsis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡